Impact of FDA Black Box Advisory on Antipsychotic Medication Use
Dorsey et al.
Arch Intern Med 2010;170:96-103.
ABSTRACT
| FULL TEXT
Drug-related cardiac pathology
Butany et al.
J. Clin. Pathol. 2009;62:1074-1084.
ABSTRACT
| FULL TEXT
Concerns about health care warnings and their impact on prescribing behaviour
Katz
CMAJ 2008;179:405-406.
FULL TEXT
Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis
Valiyeva et al.
CMAJ 2008;179:438-446.
ABSTRACT
| FULL TEXT
Using population-based routine data for evidence-based health policy decisions: lessons from three examples of setting and evaluating national health policy in Australia, the UK and the USA
Morrato et al.
J Public Health (Oxf) 2007;29:463-471.
ABSTRACT
| FULL TEXT
Cardiovascular Risk and the Thiazolidinediones: Deja Vu All Over Again?
Solomon and Winkelmayer
JAMA 2007;298:1216-1218.
FULL TEXT
Detection and reporting of drug-induced proarrhythmias: room for improvement
Darpo
Europace 2007;9:iv23-iv36.
ABSTRACT
| FULL TEXT
Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers
Bennett et al.
Arch Intern Med 2007;167:1041-1049.
ABSTRACT
| FULL TEXT
Effect of Content and Format of Prescription Drug Labels on Readability, Understanding, and Medication Use: A Systematic Review
Shrank et al.
The Annals of Pharmacotherapy 2007;41:783-801.
ABSTRACT
| FULL TEXT
ADHD drugs and cardiovascular risk.
Anders et al.
NEJM 2006;354:2296-2298.
FULL TEXT
Serious Adverse Drug Effects -- Seeing the Trees through the Forest
Gurwitz
NEJM 2006;354:1413-1415.
FULL TEXT
Adherence to black box warnings for prescription medications in outpatients.
Lasser et al.
Arch Intern Med 2006;166:338-344.
ABSTRACT
| FULL TEXT
Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board
Ray and Stein
NEJM 2006;354:194-201.
FULL TEXT
Pharmacogenetics in drug regulation: promise, potential and pitfalls
Shah
Phil Trans R Soc B 2005;360:1617-1638.
ABSTRACT
| FULL TEXT
Analysis of Aspirin-Associated Risks in Healthy Individuals
Hur et al.
The Annals of Pharmacotherapy 2005;39:51-57.
ABSTRACT
| FULL TEXT
Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis
Psaty et al.
JAMA 2004;292:2622-2631.
ABSTRACT
| FULL TEXT
Promotion and Prescribing of Hormone Therapy After Report of Harm by the Women's Health Initiative
Majumdar et al.
JAMA 2004;292:1983-1988.
ABSTRACT
| FULL TEXT
Population-Based Impact of Pneumococcal Conjugate Vaccine in Young Children
Poehling et al.
Pediatrics 2004;114:755-761.
ABSTRACT
| FULL TEXT
A Three-Part Intervention To Change the Use of Hormone Replacement Therapy in Response to New Evidence
Roumie et al.
ANN INTERN MED 2004;141:118-125.
ABSTRACT
| FULL TEXT
Safety of Patients Isolated for Infection Control
Stelfox et al.
JAMA 2003;290:1899-1905.
ABSTRACT
| FULL TEXT
What Clinicians Should Know About the QT Interval
Al-Khatib et al.
JAMA 2003;289:2120-2127.
ABSTRACT
| FULL TEXT
Principles From Clinical Trials Relevant to Clinical Practice: Part II
Califf and DeMets
Circulation 2002;106:1172-1175.
FULL TEXT
Lessons Learned From Recent Cardiovascular Clinical Trials: Part I
DeMets and Califf
Circulation 2002;106:746-751.
FULL TEXT
Implications of Cytochrome P450 Interactions When Prescribing Medication for Hypertension
Flockhart and Tanus-Santos
Arch Intern Med 2002;162:405-412.
ABSTRACT
| FULL TEXT
Postmarketing drug surveillance: what it would take to make it work
CMAJ 2001;165:1293-1293.
FULL TEXT
La surveillance postcommercialisation des medicaments : ce qu'il faudrait pour obtenir des resultats
CMAJ 2001;165:1295-1295.
FULL TEXT
Coprescribing and Codispensing of Cisapride and Contraindicated Drugs
Jones et al.
JAMA 2001;286:1607-1609.
ABSTRACT
| FULL TEXT
Liver Enzyme Monitoring in Patients Treated With Troglitazone
Graham et al.
JAMA 2001;286:831-833.
ABSTRACT
| FULL TEXT
Lessons from cisapride
CMAJ 2001;164:1269-1269.
FULL TEXT
Lecons tirees du cisapride
CMAJ 2001;164:1271-1271.
FULL TEXT
Time Trends in the Coprescribing of Cisapride and Contraindicated Drugs in Umbria, Italy
Raschetti et al.
JAMA 2001;285:1840-1841.
FULL TEXT
Drug Labeling Revisions--Guaranteed to Fail?
Woosley
JAMA 2000;284:3047-3049.
FULL TEXT